Yourgene Health PLC COVID-19 update (8543T)
March 29 2021 - 11:00AM
UK Regulatory
TIDMYGEN
RNS Number : 8543T
Yourgene Health PLC
29 March 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
COVID-19 update
Approved provider of day two and day eight coronavirus testing
for international arrivals, for both PCR and sequencing
Manchester, UK - 29 March 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that Yourgene
Genomic Services COVID-19 testing services have been approved by
the Department of Health and Social Care (DHSC). Yourgene has been
added to the UK Government's approved list as a private provider of
day two and day eight coronavirus testing for all international
arrivals(1) for both SARS-CoV-2 PCR testing and SARS-CoV-2 genome
sequencing testing services.
It was made mandatory from 15 February 2021 that international
arrivals are required to self-isolate for 10 days on return to the
UK and take a PCR test on day two and day eight of the passenger's
quarantine period. If the test result is positive and meets the
DHSC sequencing criteria, it requires sequencing in a lab for
surveillance purposes to monitor Variants of Concern and Variants
Under Investigation, with sequencing results reported directly back
to Public Health England. Yourgene will provide the routine
Clarigene SARS-CoV-2 PCR testing services and a new sequencing test
being performed from Yourgene Genomic Services using ThermoFisher's
Ion AmpliSeq(TM) SARS--CoV--2 Research Panel.
Yourgene Genomic Services can provide this COVID-19 testing
service as it meets the DHSC's 15 minimum standards(2) and has been
reviewed by UKAS, a national accreditation body recognised by the
UK Government to assess against international agreed standards. As
an experienced sequencing test laboratory, Yourgene will be able to
offer the additional service now required by the UK Government to
the Group's range of COVID-19 testing partners.
This follows on from the Company receiving confirmation that it
had been added to the UK Government's approved COVID-19 private
testing list for the 'Test to Release for International Travel'
scheme introduced on 15 December 2020 ("Test to Release"), and also
for general coronavirus testing which was also announced in
December 2020.
Lyn Rees, CEO of Yourgene commented : " Receiving approval to be
added to the Government's COVID-19 private provider list, for both
PCR testing and our sequencing service, illustrates the high
standard and service levels Yourgene has been providing under our
Genomics Services offering. We are extremely pleased to be at the
forefront of this development as travel begins to open up."
(1) - Providers of day 2 and day 8 coronavirus testing for
international arrivals - GOV.UK (www.gov.uk)
(2) - Minimum standards for private-sector providers of COVID-19
testing for 'Test to Release for international travel' - GOV.UK
(www.gov.uk)
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDFLFSSVTIAFIL
(END) Dow Jones Newswires
March 29, 2021 11:00 ET (15:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024